Table 5—

Intubation rate, outcome, length of stay (LOS) and mean time of application of noninvasive positive-pressure ventilation (NPPV) in the literature

First author [ref. no]	Study	Aetiology of ARF	Patients n	PH	P_a,CO₂ mmHg	Duration of NPPV application			LOS ICU days	Intubation n	Survival rate %
						h·day⁻¹	h	days
Meduri 30	O	Hypercapnic ARF	18	7.29	72		25	1	NA	5	94
Brochard 31	HM	COPD	13	7.29	65	7.6		3	3d	1	85
Kramer 7	PR	ARF	16	7.27	74.3	14.4		3.8±1.4	NA	5	93.7
Barbe 12	PRC	COPD	34	7.33	56	6		3	0	0	100
Fernandez 32	O	COPD	12	7.19	92	8±4		NA	7.6±1.7	3	93
Lin 10	PR	APO	50	7.40	32.9	6		NA	4±3	8	92
Mehta 13	PRC	APO	14	7.25	56	7.1±4.7		NA	2.3±3.7	1	93
Wysocki 33	PRC	COPD	21	7.39	44	7.6±11.8		1.5±1	17±19	13	67
Poponick 34	O	ARF	58	7.26	75.3	0.5		NA	4.2	13	96.5
Celikel 15	PRC	Hypercapnic ARF	15	7.28	67		26.7±16.1	NA	11.7	1	100
Wood 16	PRC	ARF	16	7.35	56.5		NA		5.8±5.5	7	75
Plant 19	PRC	COPD	118	7.32	61.7	8		3	NA	18	89.8
Antonelli 35	PRC	ARF	32	7.45	38		NA		9±7	10	71.8
Thys	PRPC	COPD and APO	10	7.28	57	1.59±0.48		1	2.7±3.5	0	80
Thys placebo	PRPC	COPD and APO	10	7.24	61	0.48±0.28		1	5.4±5.6	3	90